TRISENOX is an arsenical indicated:...In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

TRISENOX is an arsenical indicated...For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

...Rate of Event-free survival (EFS) - Rate of Event-free survival (EFS); Rate of hematological complete remission - Rate of hematological complete remission; Overall survival rate - Overall survival rate; Rate of incidence of relapse - Rate of incidence of relapse; Incidence of hematological and non-hematological toxicity episodes during treatment - Incidence of hematological and non-hematological toxicity episodes during treatment; Quality of life at the end of induction therapy and at the end of the consolidation course - Quality of life at the end of induction therapy and at the end of the consolidation course; PML/RARa fusion transcripts - PML/RARa fusion transcripts...

...- Serum creatinine ≤ 3.0 mg/dL (≤ 260 µmol/L) The confirmation of diagnosis at genetic level (microspeckled PML nuclear distribution by PGM3 monoclonal antibody and/or PML/RARa fusion by RT-PCR and/or demonstration of t(15;17) by karyotyping) will be mandatory for patient eligibility....